We incubated pro-Canakinumab or Canakinumab with MMP from 2.7 to 75 ng/mL, which is below or in the range of MMP-2 (37 ± 2.8 ng/mL) or MMP-9 (1.7 ± 0.25 μg/mL) expression level in the joint fluid of rheumatoid arthritis (RA) patients20, for 1 h and detected the IL-1β-binding ability by ELISA. This evidence concerns the gene MMP9 and rheumatoid arthritis.